STOCK TITAN

MedTech Acquisition Corporation - $MTAC STOCK NEWS

Welcome to our dedicated page for MedTech Acquisition Corporation news (Ticker: $MTAC), a resource for investors and traders seeking the latest updates and insights on MedTech Acquisition Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MedTech Acquisition Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MedTech Acquisition Corporation's position in the market.

Rhea-AI Summary
TriSalus completes merger with MedTech, stock to begin trading on Nasdaq. Cash runway through mid-2024. Advances in technology and clinical trials. Positive clinical data. TriNav net sales: $8.4M (2021), $12.4M (2022), projected $19.2M (2023). TriNav LV device receives FDA clearance. SD-101 shows immune effects in liver and blood. Phase 1 data readouts planned Q4 2023, Phase 2 trial in H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-100%
Tags
-
Rhea-AI Summary
MedTech Acquisition Corporation (Nasdaq: MTAC) has adjourned its special meeting of stockholders without conducting any business. The meeting is being held to vote on proposals related to the proposed business combination with TriSalus Life Sciences. The meeting has been rescheduled for August 8, 2023, and will be held virtually. Stockholders can attend and participate online.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
-
Rhea-AI Summary
TriSalus Life Sciences announces additional Phase 1 clinical data from PERIO-01 trial at ASCO 2023 Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.04%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
MedTech Acquisition Corporation

Nasdaq:MTAC

MTAC Rankings

MTAC Stock Data

83.86M
549.65k
84.52%
17.17%
0.05%
Shell Companies
Financial Services
Link
United States
Greenwich